For research use only. Not for human consumption. Not medical advice — consult a licensed clinician.

Immune Modulator

LL-37

Also known as: Cathelicidin

LL-37 is the only human cathelicidin antimicrobial peptide — a 37-amino-acid peptide (starting with two leucines) cleaved from the hCAP-18 precursor. It has broad-spectrum antimicrobial activity and immunomodulatory roles, but is also implicated in the pathogenesis of autoimmune and inflammatory skin diseases including psoriasis, rosacea, and lupus. Not FDA-approved; research-use only.

Where to buy · live market data

Who's worth your money for LL-37

Every current seller, ranked by independent evidence — Merit Score, latest COA purity, and live $/mg (size-normalized). Prices refresh daily. Rankings are never paid.

Top Merit pick

Highest Merit Score (96) of 20 scored sellers

$18.99/mg

$94.97 · 5mg · 99.8% purity

3 COAs
Buy code MERIT · 15% off

Best value

Lowest $/mg among scored sellers

$4.50/mg

$45.00 · 10mg · 99.9% purity

Most tested

6 independent COAs on file

$9.00/mg

$45.00 · 5mg · 99.6% purity

Average price

$11.84/mg

Sellers

46

45-day trend

+0.4%

39 of 46 sellers have a current price· 11 stale hidden· 8 unverified hidden

Prices observed from public storefronts (last 24h), normalized to $/mg. "Evidence" is Merit's 0–100 Merit Score, derived only from observable verification evidence (methodology on /about); "Purity" is the latest independent COA. Some buy links are affiliate links — Merit may earn a commission at no extra cost to you, and where a vendor offers one, the code shown gets you a discount at their checkout. Affiliate status never affects price data, ranking, or the Merit Score (full policy on /disclosure). Research use only.

Watch LL-37

Get one email when the market actually moves — no newsletter, no noise.

Compound reference

About LL-37

CAS

154947-66-7

Molecular formula

C205H340N60O53

Sequence

LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES

Typical dose range

100–400 mcg/day subcutaneous

Half-life

~4–6 hours (tissue-dependent; limited formal PK data for native LL-37)

Independent evidence

COAs for LL-37

47 third-party tests across 17 vendors. Each card links to the full report.

All 47 COAs for LL-37 →
Measured purity 91.1%–100.0% across 38 COAs
Measured purity over time
Aggregated · 3rd-party listing
99.65 %
Jul 2026
Freedom Diagnostics Moderate

For

LL-37

by Peptide Plugs· batch 175-01-DK

Aggregated · 3rd-party listing
99.60 %
Jun 2026
ILS Labs Strong

For

LL-37

by Ion Peptide· batch L375-06092026

✓ Vendor-published
99.83 %
Jun 2026
ILS Laboratories

For

LL-37

by Ion Peptide· batch L375-06092026

COA on file
Aggregated · 3rd-party listing
99.64 %
May 2026
Janoshik Analytical Limited · HPLC

For

LL-37

by Verified Peptides· batch LL05260305C

Aggregated · 3rd-party listing
99.64 %
May 2026
Janoshik Analytical Limited

For

LL-37

by Verified Peptides

Aggregated · 3rd-party listing
94.08 %
May 2026
Janoshik Analytical Limited

For

LL-37

by Verified Peptides· batch LL025602005C

Aggregated · 3rd-party listing
91.08 %
May 2026
Freedom Diagnostics Moderate

For

LL-37

by Real Peptides· batch Black Cap

Aggregated · 3rd-party listing
99.94 %
Mar 2026
Kovera Labs

For

LL-37

by Ion Peptide· batch LL375-03232026

✓ Vendor-published
99.94 %
Mar 2026
Kovera Labs

For

LL-37

by Ion Peptide· batch LL375-03232026

COA on file
Aggregated · 3rd-party listing
99.96 %
Mar 2026
Freedom Diagnostics Moderate

For

LL-37

by Modern Research Peptides· batch GCEMHK0226

Aggregated · 3rd-party listing
99.50 %
Feb 2026
Janoshik Analytical Limited

For

LL-37

by EZ Peptides· batch EZP-LL371002172026-01

✓ Vendor-published
99.50 %
Feb 2026
Janoshik Analytical Limited

For

LL-37

by EZ Peptides· batch EZP-LL37100217-2026-01

COA on file
Aggregated · 3rd-party listing
99.47 %
Feb 2026
Vanguard Laboratory Strong

For

LL-37

by Peptidology· batch 1669

✓ Vendor-published
99.04 %
Jan 2026
Janoshik Analytical Limited

For

LL-37

by Ruo Bio

COA on file
Aggregated · 3rd-party listing
99.93 %
Jan 2026
Freedom Diagnostics Moderate · HPLC

For

LL-37

by Simple Peptide· batch L1-05-01162026-J

Aggregated · 3rd-party listing
99.83 %
Jan 2026
Freedom Diagnostics Moderate

For

LL-37

by Southern Aminos· batch LL050126A

Aggregated · 3rd-party listing
99.93 %
Jan 2026
Freedom Diagnostics Moderate · HPLC

For

LL-37

by Simple Peptide· batch LL10-37011220236-J

Aggregated · 3rd-party listing
99.70 %
Jan 2026
Freedom Diagnostics Moderate · HPLC

For

LL-37

by MedGe Peptides· batch LL375LT12

Aggregated · 3rd-party listing
99.70 %
Jan 2026
Freedom Diagnostics Moderate · HPLC

For

LL-37

by MedGe Peptides· batch LL375LT12

Aggregated · 3rd-party listing
99.84 %
Jan 2026
Freedom Diagnostics Moderate · HPLC

For

LL-37

by Simple Peptide· batch LL37L2092025-J

Aggregated · 3rd-party listing
99.82 %
Jan 2026
Chromate Moderate

For

LL-37

by Orbitrex Peptides· batch LL5126

Aggregated · 3rd-party listing
99.82 %
Dec 2025
Chromate Moderate

For

LL-37

by Orbitrex Peptides

Aggregated · 3rd-party listing
99.83 %
Dec 2025
BioRegen Moderate

For

LL-37

by Real Peptides

Aggregated · 3rd-party listing
99.82 %
Oct 2025
Freedom Diagnostics Moderate

For

LL-37

by Kimera Chems· batch KC-L37-BLU1

Research depth

20 citations indexed for LL-37

All research on LL-37 →

review · 2026

LL-37: Biological Mechanisms and Emerging Therapeutic Applications in Intestinal Disease

Human cathelicidin peptide LL-37 is encoded by the CAMP gene and plays a key role in innate immunity. It maintains intestinal homeostasis through antibacterial, immunomodulation, and tissue repair functions.

Study · 2026

LL-37 and citrullinated-LL-37 enhances oxylipins: citrullination attenuates LL-37-mediated COX-2-dependent chemokine response in human bronchial epithelial cells

BACKGROUND: During airway inflammation, chemokines, oxylipins (bioactive lipids) and cationic host defence peptides (CHDP) are enhanced in the lungs. However, the interplay of these molecules in the process of airway inflammation is not fully resolved.

review · 2026

β-Amyloid (Aβ) and Human Cathelicidin LL-37: Two Sides of the Same Coin?

Study · 2026

A degradable hydrogel scaffold incorporating the LL-37 for gingival soft tissue regeneration

Gingival recession exposes the roots, leads to dentin hypersensitivity, and heightens the progression of periodontitis, and poses a threat to oral health and appearance. Conventional treatment uses autogenous palatal grafts, requiring a second surgical site and adding patient discomfort.

animal · 2026

Melanoma exosomal hsa-miR-221-5p suppresses keratinocyte LL-37 to promote tumor progression

Melanoma progression is regulated by not only tumor-intrinsic factors but also dynamic crosstalk with the surrounding epidermis. Here, we observed spatial suppression of cathelicidin LL-37 in tumor-adjacent epidermis compared with that in distal regions in clinical specimens.

review · 2026

β-Amyloid (Aβ) and Human Cathelicidin LL-37: Two Sides of the Same Coin?

Physiologically produced circulating β-amyloid (Aβ) exerts critical physiological functions. Although Aβ is a key player in Alzheimer's disease (AD), it may initially be beneficial at the onset of infection.